+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Qiagen NV (QGEN) - Product Pipeline Analysis, 2026 Update

  • PDF Icon

    Report

  • 128 Pages
  • August 2026
  • GlobalData
  • Qiagen N.V.
  • ID: 5637091
Qiagen NV is a life-science and diagnostics company that helps laboratories turn biological samples into clear test results and research insights. The company’s product portfolio includes the collection, stabilization, and purification of DNA, RNA, and proteins from materials such as blood and tissue. Qiagen offers tools and kits for key lab steps like PCR testing, sequencing, and studying gene activity and epigenetics, plus specialized solutions for exosomes and circulating tumor cells. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical, biotechnology and life sciences research markets. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Qiagen NV
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

List of Tables
Section 1 - About the Company
  • Avebe UA - Key Facts
  • Avebe UA - Key Employees
  • Avebe UA - Major Products and Services
  • Avebe UA - History
  • Avebe UA - Company Statement
  • Avebe UA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Avebe UA - Business Description
  • Product Category: By-products
  • Performance
  • Product Category: Modified Starch
  • Performance
  • Product Category: Starch
  • Performance
  • Geographical Segment: European Union
  • Performance
  • Geographical Segment: Rest of Europe
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • R&D Overview
  • Avebe UA - Corporate Strategy
  • Avebe UA - SWOT Analysis
  • SWOT Analysis - Overview
  • Avebe UA - Strengths
  • Avebe UA - Weaknesses
  • Avebe UA - Opportunities
  • Avebe UA - Threats
  • Avebe UA - Key Competitors
Section 3 - Company’s Recent Developments
  • Dec 17, 2025: Iris Bouwers Appointed to the Supervisory Board of Royal Avebe
  • Dec 16, 2025: Royal Avebe Presents Integrated Annual Report 2024/2025 and Outlines Potato Market Challenges
  • May 06, 2025: Royal Avebe hires Saskia de Groot as new CHRO
Section 4 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Avebe UA, Key Facts
  • Avebe UA, Key Employees
  • Avebe UA, Major Products and Services
  • Avebe UA, History
  • Avebe UA, Other Locations
  • Avebe UA, Subsidiaries
  • Avebe UA, Key Competitors